If you’ve stood in the supplement aisle (or scrolled through one on Amazon!) you’ve probably noticed the many different types of omega-3 products. Fish oil and krill oil refers to the source of the omega 3 fatty acid. Both fish and krill oil deliver EPA and DHA, the omega-3s most studied for brain, cardiovascular, and metabolic health. But, they package those fatty acids differently at the molecular level, and that packaging affects how your body absorbs and ultimately uses them. This is particularly noted in the brain.
For patients focused on cognitive resilience through midlife, perimenopause, or preconception planning, this changes how we think about dosing, timing, and which form may be worth the extra cost.
Think about it as two different “delivery trucks”
Omega-3 fatty acids never float around on their own, they’re always attached to a backbone molecule. The two forms relevant here are:
- Triglyceride (TG) form — the natural form found in fatty fish and standard fish oil, where three fatty acid chains (often including EPA/DHA) are bonded to a glycerol backbone. Concentrated fish oil supplements may instead use ethyl esters (EE) or re-esterified triglycerides (rTG), which are lab-modified versions of the same basic triglyceride chemistry (1).
- Phospholipid (PL) form — the dominant form in krill, where EPA/DHA are attached to a phosphate-and-choline-containing head group, mainly as phosphatidylcholine. Roughly 30–65% of the fatty acids in krill are bound this way, compared with fish, which stores fatty acids almost entirely as triglycerides (2).
The forms are digested differently
Triglyceride-form omega-3s need pancreatic lipase to snip off the fatty acid chains, releasing free fatty acids that intestinal cells then reassemble into new triglycerides, package, and ship out via the lymphatic system. This process is efficient, but it depends on having enough dietary fat present at the same meal to trigger normal fat digestion (3).
Phospholipid-form omega-3s are cleaved instead by a different enzyme (phospholipase A2), generating a related molecule (called lysophosphatidylcholine, or, LPC). This pathway appears to be somewhat less dependent on co-ingested fat and, in several — though not all — head-to-head trials, gets EPA and DHA into the bloodstream faster and to a greater degree per milligram than standard fish oil triglycerides do (4). It’s worth noting the evidence isn’t unanimous — some carefully dose-matched trials have found essentially equivalent blood levels between fish oil and krill oil over several weeks (5), and a recent meta-analysis found krill’s advantage is clearest at lower doses (under roughly 2,000 mg/day), narrowing at higher doses (6).
The bottleneck for the brain
The brain cannot manufacture DHA on its own, it must import essentially all of it from the bloodstream (7). The transporter responsible for pulling DHA across the blood-brain barrier (called MFSD2A) is highly selective – it only recognizes DHA when it’s in phospholipid form, it does not transport DHA that’s still bound in a triglyceride (8, 9). We know how essential this single transporter is because rare humans born with non-functioning MFSD2A develop a severe, lethal microcephaly syndrome from inadequate brain DHA delivery (10).
So is triglyceride-form fish oil useless for the brain?
No, the brain can still use it, just after a little processing. When you take an omega 3 supplement, whether it started as triglyceride or phospholipid, it gets absorbed into the bloodstream and passes through the liver. The liver repackages the omega 3 fatty acids into various carriers, including the form that can pass the blood-brain barrier, the phospholipid form. The phospholipid form that is released from the liver is considered the primary source of the circulating DHA pool that the brain draws from via that MFSD2A receptor (11).
In other words, when you take the triglyceride form of omega 3’s, from fish oil, your body takes time to do a “convert and release” process, facilitated by the liver, that converts the omega 3 fatty acids into the brain’s preferred form. It’s less a passive warehouse and more an active conversion pipeline — but functionally, it produces the same result over time: usable DHA reaching the brain, just with an extra metabolic step in between.
Because krill’s DHA already arrives largely in the phospholipid form accepted by the brain, that form does not require the same degree of liver reprocessing. This is a plausible mechanistic explanation for krill oil’s edge in several blood-level trials. However, it’s important to be precise about what’s actually been measured: most human comparison studies track DHA in plasma or red blood cells, not directly in brain tissue (which isn’t biopsied in living patients). Whether krill’s blood-level advantage translates into measurably higher brain DHA content in humans is still an open, active research question, with mixed results in animal models so far (12,13).
What about prescription omega-3 (called Lovaza)?
Patients sometimes ask whether a prescription option is simply the “strongest” or “best” choice. The most common one, Lovaza (omega-3-acid ethyl esters), is worth placing in this same TG-vs-PL framework, because it’s actually a third chemical form.
- Chemical form: Lovaza is an ethyl ester (EE), not a natural triglyceride or a phospholipid. Each 1 g capsule contains roughly 465 mg EPA and 375 mg DHA (at least 900 mg total omega-3 ethyl esters), concentrated and purified from fish oil (14).
- What it’s actually approved for: Lovaza is FDA-approved only as an adjunct to diet for severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL) — it is a targeted lipid-lowering drug, not an approved treatment for brain health or cognition (15). Unlike icosapent ethyl (Vascepa), which carries an added cardiovascular risk-reduction indication, Lovaza’s label states its effect on cardiovascular events hasn’t been established (16).
- Dosing: 4 g/day (typically four 1 g capsules), and clinical trials administered it with meals (17).
- Bioavailability nuance: Ethyl esters require an extra hydrolysis step by pancreatic carboxyl ester lipase before absorption, and this step is strongly fat-dependent. In the fasted state, ethyl ester bioavailability can drop several-fold compared with natural triglyceride or free-fatty-acid forms, which is why the label emphasizes taking it with a meal (18,19).
- Purity and regulation: As an FDA-regulated drug, Lovaza undergoes standardized purification and potency testing that over-the-counter supplements aren’t required to meet — a genuine advantage when a diagnosed lipid disorder requires a guaranteed, high, consistent dose (20).
Lovaza is a legitimate, well-studied therapy for a specific problem (dangerously high triglycerides), and like fish oil it’s still an ethyl-ester/triglyceride-family molecule that must go through the same liver-conversion step described above before any of its DHA is usable by the brain. If your triglycerides are in a normal range and your goal is general or cognitive omega-3 support, the over-the-counter fish oil or krill oil options above remain the appropriate choice; if you have clinically severe hypertriglyceridemia, Lovaza (or alternatives like Vascepa) is worth discussing with your physician as a prescription option.
Summary: Consistency matters more than any single dose form
- Total, consistent intake is the foundation. Most guidelines recommend 250–500 mg combined EPA+DHA daily for general health, with higher intakes (1–2 g/day) studied for cognitive support (21). Hitting this target reliably, in whichever form you tolerate and can afford, matters more than the form itself. Durable brain benefits build over months, not single doses.
- Take fish oil (triglyceride form) with a meal containing some fat. Because TG-form absorption depends on normal fat digestion, taking it on an empty stomach may reduce uptake.
- Krill oil may offer an efficiency edge at lower doses, meaning some patients can reach comparable blood levels with a smaller capsule — useful if you’re sensitive to fish-oil aftertaste/reflux or prefer a lower pill burden. It also comes with astaxanthin, a carotenoid antioxidant not found in fish oil.
- Neither form is “wasted.” Fish oil’s triglyceride-bound DHA is still converted by the liver into the phospholipid form your brain requires — it just takes an intermediate metabolic step, which is normal and effective in a healthy liver.
- Give it time. Because brain DHA turnover is so slow, judge any omega-3 strategy over a 2–3 month window (or by checking an Omega-3 Index) rather than expecting an immediate shift.
If you’d like your current omega-3 status checked with an Omega-3 Index test, or want a personalized recommendation on dose and form based on your health history, reach out to schedule a visit.
